| Summary of royalty and commercial payment receivable and contingent consideration activities |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the three months ended March 31, 2026 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2026 |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Balance as of March 31, 2026 |
Twist |
|
$ |
15,000 |
|
$ |
— |
|
$ |
15,000 |
Daré (XACIATO) |
|
|
21,993 |
|
|
(2) |
|
|
21,991 |
Palobiofarma |
|
|
10,000 |
|
|
— |
|
|
10,000 |
Kuros |
|
|
4,500 |
|
|
— |
|
|
4,500 |
Castle Creek |
|
|
4,395 |
|
|
— |
|
|
4,395 |
Total |
|
$ |
55,888 |
|
$ |
(2) |
|
$ |
55,886 |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the three months ended March 31, 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2025 |
|
|
Acquisition of Royalty and Commercial Payment Receivables |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Balance as of March 31, 2025 |
Twist |
|
$ |
15,000 |
|
$ |
— |
|
$ |
— |
|
$ |
15,000 |
Daré (XACIATO) |
|
|
21,999 |
|
|
— |
|
|
(2) |
|
|
21,997 |
LadRx (MIPLYFFA) |
|
|
4,850 |
|
|
— |
|
|
(413) |
|
|
4,437 |
Palobiofarma |
|
|
10,000 |
|
|
— |
|
|
— |
|
|
10,000 |
Kuros |
|
|
4,500 |
|
|
— |
|
|
— |
|
|
4,500 |
Castle Creek |
|
|
— |
|
|
4,395 |
|
|
— |
|
|
4,395 |
Total |
|
$ |
56,349 |
|
$ |
4,395 |
|
$ |
(415) |
|
$ |
60,329 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the three months ended March 31, 2026 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2026 |
|
Income from Purchased Receivables Under the EIR Method |
|
Receipt of Royalty and Commercial Payments |
|
|
Balance as of March 31, 2026 |
Affitech (VABYSMO) |
|
$ |
17,555 |
|
$ |
6,696 |
|
$ |
(11,945) |
|
$ |
12,306 |
LadRx (MIPLYFFA) |
|
|
3,765 |
|
|
2,297 |
|
|
(1,069) |
|
|
4,993 |
Aptevo (IXINITY) |
|
|
5,893 |
|
|
246 |
|
|
(479) |
|
|
5,660 |
Total |
|
$ |
27,213 |
|
$ |
9,239 |
|
$ |
(13,493) |
|
$ |
22,959 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during three months ended March 31, 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2025 |
|
|
Income from Purchased Receivables Under the EIR Method |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Payment of Sales-Based Milestone |
|
|
Balance as of March 31, 2025 |
Affitech (VABYSMO) |
|
$ |
13,105 |
|
$ |
5,817 |
|
$ |
(11,145) |
|
$ |
3,000 |
|
$ |
10,777 |
Aptevo (IXINITY) |
|
|
6,628 |
|
|
253 |
|
|
(561) |
|
|
— |
|
|
6,320 |
Total |
|
$ |
19,733 |
|
$ |
6,070 |
|
$ |
(11,706) |
|
$ |
3,000 |
|
$ |
17,097 |
|
| Summary of income from purchased receivables under the cost recovery method and EIR method |
The following table summarizes income recognized from purchased receivables under the EIR method and cost recovery method during the three months ended March 31, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2026 |
|
2025 |
Affitech (VABYSMO) |
|
$ |
6,696 |
|
$ |
5,817 |
LadRx (MIPLYFFA) |
|
|
2,297 |
|
|
— |
Aptevo (IXINITY) |
|
|
246 |
|
|
253 |
Total income from purchased receivables under the EIR method |
|
$ |
9,239 |
|
$ |
6,070 |
|
|
|
|
|
|
|
Viracta (OJEMDA) |
|
$ |
2,769 |
|
$ |
5,525 |
Total income from purchased receivables under the cost recovery method |
|
$ |
2,769 |
|
$ |
5,525 |
|